Refine by
Ocular Disease Suppliers & Manufacturers
10 companies found
based inSchlieren, SWITZERLAND
We want to empower people to deal with their malignant cells through their own immune system just like we deal with viral infections. Today’s cancer immunotherapies are powerful but, to the detriment of their effect, not very tumor-selective. ...
CDR-Life’s T cell engaging antibodies are potentially transformative in the field of cancer immunotherapies» Prof. Markus G. Manz, MD, Head of Medical Oncology and Hematology at University Hospital and University of Zurich, Switzerland. ...
based inCambridge, MASSACHUSETTS (USA)
Alnylam is the Leading RNAi Therapeutics Company. Alnylam has led the translation of RNAi (RNA interference) from Nobel Prize-winning discovery into an innovative, entirely new class of medicines. Founded in 2002 by a team of distinguished life ...
based inWellesley Heights, MASSACHUSETTS (USA)
Novel point-of-care diagnostics for earlier disease detection. SANO Diagnostics is developing a range of disposable, cost-effective point-of-care diagnostics to detect the early onset of inflammation in several disease states. We are a development ...
Simplifying detection of Inflammatory Markers relevant to multiple diseases. SANO Diagnostics’ technology is founded on the ability to detect certain markers of inflammation, a class of proteins known as ...
based inWest Sussex, UNITED KINGDOM
A British company and the only manufacturer of intraocular lenses in the UK. Rayner is leading the way in ophthalmic innovation with IOLs and ophthalmic solutions designed to provide surgeons and patients with the best visual outcomes. When Sir ...
based inVancouver, BRITISH COLUMBIA (CANADA)
InMed Pharmaceuticals is a global leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, including clinical and preclinical programs targeting the treatment of diseases with high unmet ...
INM-088 is a topical eye drop formulation under development for the treatment of glaucoma. The active pharmaceutical ingredient (API) in INM-088 is cannabinol, also known as CBN, a rare cannabinoid showing promise in its potential to provide ...
based inBalerna, SWITZERLAND
APR Applied Pharma Research s.a. (APR) is a Swiss Pharma company dedicated to providing patients suffering from rare diseases with innovative treatments that make a real difference in their life. Our focus as a Swiss global health care company is ...
based inMiami, FLORIDA (USA)
Bio-Tissue, Inc. was founded in 1997 to help address unmet needs for improved surgical and therapeutic alternative to treat ocular surface conditions; one that would serve as a non-immunogenic tissue replacement and would help facilitate tissue ...
PROKERA biologic corneal bandage devices are used by eye doctors around the world to heal and treat ocular conditions such as keratitis, moderate to severe dry eye disease, recurrent corneal erosions, filamentary ...
based inCambridge, MASSACHUSETTS (USA)
At BlueRock, our mission is to create authentic cellular medicines to reverse devastating diseases, with the vision of improving the human condition. Until recently, scientists believed that mature adult cells were permanently locked into their ...
With our cell+gene platform, BlueRock is aiming to redefine the very way we treat disease, moving from addressing mere symptoms to restoring health lost to cell damage or degeneration. Instead of prescribing a pill to treat tremors in patients with ...
based inShirley, NEW YORK (USA)
Creative Biogene provides kits, reagents, and services that help researchers explore questions about gene discovery, regulation, and function. Creative Biogene holds a leadership position in the global market and is committed to improving the human ...
We mainly use the three approaches to abrogate gene function in zebrafish: stable lines carrying mutations (mutants); morpholino-based knock-down of gene function; and use of CRISPR/Cas9 gene editing to disrupt gene function in injected embryos. ...
based inSan Diego, CALIFORNIA (USA)
An emerging San Diego-based clinical stage eye care pharmaceutical company developing and commercializing a proprietary ocular drug delivery portfolio focused on glaucoma, dry eye and ocular allergy initially. We are using our proprietary MediPrint ...
We have proprietary printing technology and ink that allows for the sustained, continuous release of ophthalmic drugs via contact lenses and it is called the MediPrint process. Our unique process results in a novel way to for treat various eye ...